Please use this identifier to cite or link to this item:
|Title:||Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.|
|Citation:||HEALTH TECHNOL ASSESS, 2011, 15 (10), pp. i-329|
|Abstract:||Etanercept, infliximab and adalimumab are licensed in the UK for the treatment of active and progressive psoriatic arthritis (PsA) in adults who have an inadequate response to standard treatment.|
|Appears in Collections:||Published Articles, Dept. of Health Sciences|
Files in This Item:
There are no files associated with this item.
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.